Marine Sponge Compounds Show Promise as Novel Leishmaniasis Treatments
Key Insights
Japanese researchers have isolated 10 natural compounds called onnamides from Okinawan marine sponges, with two showing exceptional activity against Leishmania major (search) parasites.
Onnamide A (search) and 6,7-dihydro-onnamide A (search) demonstrated superior potency and safety compared to current leishmaniasis (search) treatments, while operating through distinct mechanisms that could overcome drug resistance.
The compounds showed strong selectivity for parasites over human cells and may enable shorter treatment durations at lower concentrations.
Japanese researchers have discovered potent new compounds from marine sponges that could transform the treatment of leishmaniasis (search), a neglected tropical disease affecting around 12 million people worldwide. The study, published in Marine Biotechnology, represents a significant breakthrough in addressing a disease that disproportionately affects poor communities with limited access to medical care.
Novel Compounds from Okinawan Waters
A research team led by Associate Professor Kanami Mori-Yasumoto from Tokyo University of Science isolated 10 natural compounds from marine sponges collected in Manza, Okinawa. The compounds, derived from Theonella sponges, belong to a group called onnamides and demonstrated remarkable effectiveness against Leishmania major (search), a parasite commonly causing skin leishmaniasis (search).
Two compounds emerged as particularly promising candidates: onnamide A (search) and 6,7-dihydro-onnamide A (search). Laboratory testing revealed these compounds showed potency and safety far exceeding current treatments, with strong activity at low concentrations and minimal toxicity to human cells.
Addressing Critical Treatment Gaps
Leishmaniasis (search), caused by Leishmania protozoa, is characterized by painful skin sores that can develop into deep ulcers and leave permanent scars. The disease affects an estimated 12 million people in over 90 countries, with the burden greatest in low-income regions where healthcare resources are limited.
Current treatments face significant limitations. Existing drugs such as antimonial compounds (search) and amphotericin B often cause serious side effects, are highly toxic and expensive, preventing many patients from completing therapy. Drug resistance is also becoming more common, and the lack of vaccines and efficient diagnostic tools hinders disease control efforts.
Distinct Mechanisms and Structural Insights
The research revealed that onnamide A (search) appears to combat L. major through a mechanism distinct from amphotericin B, which works by interacting with ergosterol in the parasite's cell membrane. This novel approach could help scientists overcome current drug resistance challenges.
The study also identified the structure of onnamide G (search) for the first time, highlighting the structural diversity and potential mechanisms within the onnamide family. This characterization offers new opportunities to explore structure-activity relationships in this class of molecules.
Clinical Development Pathway
The onnamides demonstrated favorable properties for drug development, including effectiveness at low concentrations that may translate into shorter treatment durations and reduced dosing frequency. However, researchers noted that further analyses are required to confirm cost-effectiveness, in vivo efficacy, and pharmacokinetics before clinical development can begin.
"It may also be possible to apply these compounds to other protozoan diseases, such as Chagas disease (search) and African sleeping sickness (search)," said Dr. Mori-Yasumoto, suggesting broader therapeutic potential beyond leishmaniasis (search).
Sustainable Production and Future Prospects
Ongoing research is evaluating onnamides as lead compounds under the AMED Drug Discovery Booster program, which supports translating promising drug candidates into new medicines. Efforts are underway to develop sustainable production methods using symbiotic bacteria associated with marine sponges.
"It may be possible to develop mass-production platforms for onnamide synthesis using modern culturing technology and symbiotic bacteria, ensuring a sustainable source," Dr. Mori-Yasumoto explained.
Dr. Tanaka emphasized the significance of Okinawa's marine biodiversity: "The seas of Okinawa are home to abundant world-class biological resources. In this study, we discovered anti-leishmanial active compounds from marine sponges – treasures of the ocean – that have the potential to surpass existing drugs."
The researchers hope this work represents a crucial step in addressing leishmaniasis (search) and other parasitic diseases. "This research is the first step in bringing new treatment options to patients around the world and represents a significant milestone in Japan's contribution to research on neglected tropical diseases," said Dr. Mori-Yasumoto.